Overview

A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder

Status:
Completed

Trial end date:
2007-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.

Phase:

Phase 3

Details

Lead Sponsor:

Janssen-Cilag International NV

Treatments:

Aripiprazole
Quetiapine Fumarate
Risperidone